The ADMIRAL phase 3 trial, designed for relapsed/refractory (R/R) FLT3-mutated AML patients, recently demonstrated the superiority of gilteritinib as single agent over the control treatment arm [8], which was determined by investigators prior to 2:1 randomization between mitoxantrone, etoposide, cytarabine (MEC), fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubicin (FLAG-IDA), azacitidine (AZA) or low-dose cytarabine (LDAC). This evidence concerns the gene FLT3 and acute myeloid leukemia.